Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Total 13F shares
-
36,621,247
-
Share change
-
+2,119,711
-
Total reported value
-
$176,523,672
-
Put/Call ratio
-
278%
-
Price per share
-
$4.82
-
Number of holders
-
60
-
Value change
-
+$9,038,590
-
Number of buys
-
28
-
Number of sells
-
31
Institutional Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q3 2022
As of 30 Sep 2022,
ADC Therapeutics SA - Common Shares (ADCT) was held by
60 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
36,621,247 shares.
The largest 10 holders included
FMR LLC, Redmile Group, LLC, JPMORGAN CHASE & CO, ALLIANCEBERNSTEIN L.P., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), EVENTIDE ASSET MANAGEMENT, LLC, PICTET ASSET MANAGEMENT SA, PRICE T ROWE ASSOCIATES INC /MD/, Vantage Consulting Group Inc, and GCM Grosvenor Holdings, LLC.
This page lists
60
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.